Application 021466
- Type
- NDA
- Sponsor
- PFIZER
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | VFEND | VORICONAZOLE | Tablet; Oral | 50MG | No | No |
| 002 | VFEND | VORICONAZOLE | Tablet; Oral | 200MG | No | No |
| 003 | VFEND | VORICONAZOLE | Injectable; Iv (Infusion) | 200MG/VIAL | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| VORICONAZOLE | VORICONAZOLE | Novel Laboratories, Inc. | 53ecce53-57b8-4af1-b4ac-7d37eb25711f | 2023-12-05 | Warnings, Adverse reactions | VORICONAZOLE |
| Voriconazole | VORICONAZOLE | Xellia Pharmaceuticals USA LLC | 9ec6eda2-2f15-423b-9ec6-819379a426e1 | 2023-01-11 | Warnings, Adverse reactions | VORICONAZOLE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.